UNSPSC 51102877: Ambroxol/clarithromycin

This classification denotes a combination drug composed of two constituents: a mucolytic and a macrolide antibiotic, as more fully appears. The first constituent, ambroxol (51162702), is an expectorant and amino-alcohol that bears the molecular formula C13H18BR2N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 200168S0CL, chemically known as 4-[(2-Amino-3,5-dibromobenzyl)amino]cyclohexanol but more generally known as ambroxol [EU/ESIS 242-500-3]; ambroxol comes in forms acefyllinate [0HM1E174TN], base, and hydrochloride [CC995ZMV90].

UNSPSC 51102877 Ambroxol/clarithromycin is a Commodity code for pharmaceutical products; state and local procurement activity under this code reflects purchases of specific branded or generic medications—both matching the code name and diverging into related therapeutics—for public health agencies, emergency response programs, and community health departments. State and local governments use this code to acquire medications through piggyback contracts tied to cooperative purchasing consortiums, direct competitive bidding, and warehouse supply agreements. Recent solicitations show purchases spanning antibiotic tablets (doxycycline, ciprofloxacin) and emergency-response pharmaceuticals (naloxone) acquired through Invitation for Bid processes. Issuing bodies include state departments of public health and county health and emergency-management offices; Illinois Department of Public Health and Seminole County, Florida appear in recent activity.

Activity under the code concentrates in Illinois and Florida based on recent postings. The Illinois Department of Public Health awarded a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 (Bid Number 26-482DPH-PREPD-B-53392) for doxycycline hyclate and ciprofloxacin hydrochloride tablets with a total award of $2,999,999.11 over twelve months plus renewal options; this was a completed IFB award, not an open solicitation. Seminole County, Florida posted an IFB (Number IFB60459723LAS) on June 30, 2026 with a response deadline of July 26, 2023 (note: date discrepancy in source) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries, with a two-year initial term and one-year renewal option.